Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Waters Secures FDA 510(k) Clearance for Leukemia and Lymphoma Flow Cytometry Tests

Waters Corporation announced that the BD OneFlow LST Test and BD OneFlow B-CLPD T1 Test have received U.S. Food and Drug Administration (FDA) 510(k) clearance. This clearance enables commercialization in the U.S. and provides pathologists and...

Bayer’s SUNHARBO® (asundexian) Receives FDA Approval for Stroke Risk Reduction

Bayer announced that the U.S. Food and Drug Administration (FDA) has approved SUNHARBO® (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicated in combination with antiplatelet therapy to reduce the risk of stroke...

BE BOLD: BIMZELX® (bimekizumab-bkzx) demonstrates superior joint response rates versus SKYRIZI® (risankizumab-rzaa) at Week 16, with sustained clinical improvements through Week 24

UCB, a global biopharmaceutical company, announced Week 24 data for BIMZELX® (bimekizumab-bkzx) from BE BOLD, building on the study's previously reported Week 16 results, which demonstrated statistically significant superiority in ACR50 joint...

Johnson & Johnson announces that ICOTYDE® (icotrokinra), a once-daily targeted oral peptide, delivers significant improvements in psoriatic arthritis disease activity among biologic-naïve patients

Johnson & Johnson announced positive results from a Phase 3 study investigating ICOTYDE® (icotrokinra) in biologic-naïve adults with active psoriatic arthritis (PsA).a,b ICOTYDE is the first and only targeted oral peptide that precisely blocks the...

Lilly and Hims & Hers expand access to Lilly's FDA-approved medicines

Eli Lilly and Company announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will...

Roche Receives FDA 510(k) Clearance for New cobas® eplex Respiratory Pathogen Panel 3, Enabling Customized Respiratory Testing to Meet Local Patient Needs

Roche announced the U.S. Food and Drug Administration (FDA) 510(k) clearance of the cobas® eplex respiratory pathogen panel 3 (RP3). Designed for the automated cobas® eplex system, this flexible syndromic test offers up to five customizable panel...

Superpower Launches Peptide Services, Connecting Comprehensive Blood Testing With Prescription Peptide Care

Superpower, the human health company on a mission to enhance and extend human life, announces the launch of Superpower Peptides. Members can now sign up for pre-orders for prescribed peptide treatments, following clinical consults. The...

Pythia Labs Launched AI-Designed Antibodies for Hard-to-Drug Targets

Pythia Labs, a biotechnology company building frontier AI models for therapeutic discovery, announced its launch alongside a preprint in bioRxiv introducing Pythia-1, the all-atom generative model at the core of its antibody design platform....

Pythia Labs Launched AI-Designed Antibodies for Hard-to-Drug Targets

Pythia Labs, a biotechnology company building frontier AI models for therapeutic discovery, announced its launch alongside a preprint in bioRxiv introducing Pythia-1, the all-atom generative model at the core of its antibody design platform....

Niagen Bioscience Launched Niagen™ Plus Liquid At-Home Injections to Support Its Telehealth Expansion

Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announced the launch of the clinician-directed, prescription-only pharmaceutical-grade Niagen™ At-Home Injection...

Niagen Bioscience Establishes Skincare as a Permanent Tru Niagen® Category with the Launch of Dermatologist-Tested Niagen NanoCloud™ as a Core Product

Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the debut of Tru Niagen® Skincare, a permanent new category in the core Tru Niagen line, led by...

Arkayli Biopharma Inc. Receives FDA Study May Proceed Response to IND and NIH SBIR Grant to Advance Clinical Development of ARK001 for a Rare Pediatric Disease

Arkayli BioPharma Inc. a biopharmaceutical company dedicated to developing innovative therapies for rare dermatologic conditions, announced that the U.S. Food and Drug Administration (FDA) has responded to its Investigational New Drug (IND)...

SHARx Warns: The Pharmacy Budget Trap — Why Discounts Alone Cannot Control Total Spending

A larger rebate does not guarantee lower pharmacy spending, warns Paul Pruitt, Chief Growth Officer and Co-Founder of SHARx, a procurement management solution for high-cost prescription drugs. Demand for GLP-1 medications, specialty drugs and...

Niagen Bioscience Puts 25 Years of NAD+ Science Behind “Don’t Get Old. Age Better.®” — a New Campaign for Its Niagen® Brand Featuring Legendary Surfer Kelly Slater

Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of “Don't Get Old. Age Better.®,” a new brand campaign for its Niagen® (patented...

Upsher-Smith Launched Fluvoxamine Maleate Extended-Release Capsules

Upsher-Smith Laboratories, LLC a subsidiary of Bora Pharmaceuticals Co., Ltd. (6472.TW and BORAY.OTCQX), today announced the recent launch of Fluvoxamine Maleate Extended-Release Capsules in 100 mg and 150 mg strengths. According to IQVIA, the...

Cresilon launched next-generation TRAUMAGEL.

Cresilon Inc. a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, announced the launch of TRAUMAGEL®'s next generation, which officially debuts at EMS World Expo 2026 in Orlando, Florida. This next generation...

SHARx Focuses on Rx Continuity for Employers and Patients as Customs Requirements Change

Changes to customs procedures could affect some pathways used by Americans to obtain lower-cost prescription medications. The industry experts at SHARx, a supply-chain and procurement management company, are advocating to ensure those in need of...

Tsingke Enables High-Throughput Validation of AI-Designed Proteins and Antibodies

Tsingke announced an integrated high-throughput validation workflow designed to help researchers experimentally evaluate large libraries of AI-designed proteins and antibodies. Combining gene synthesis, parallel expression, high-throughput...

Tsingke Enables High-Throughput Validation of AI-Designed Proteins and Antibodies

Tsingke announced an integrated high-throughput validation workflow designed to help researchers experimentally evaluate large libraries of AI-designed proteins and antibodies. Combining gene synthesis, parallel expression, high-throughput...

Stasis Introduces the First Day-and-Night Supplement System Built for Children Who Take Stimulants

Stasis, the company behind the first supplement system designed to be taken alongside stimulants, today introduced Stasis Kids, a day-and-night nutritional supplement system made for children ages 6 to 17. In 2023, 16.5 million people in the...